Skip to Main Content

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather modest. We plan to hang with our short people, catch up on our reading and napping, and promenade with the official mascots. And what about you? Winter is clearly on its way, so perhaps you want to give the economy another boost by purchasing a sweater or something else that is warm and fuzzy. You could make time to reach out to someone special. Or given recent events, this may be a good time to take stock and count your blessings, not your faults. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon …

AstraZeneca (AZN) disclosed that its Imfinzi immunotherapy did not meet the main goal of improving survival rates for patients with the most advanced form of lung cancer, putting pressure on its shares, Reuters writes. The study, known as MYSTIC, was among the industry’s most anticipated clinical experiments and was viewed as central to proving the value of its new drug pipeline and future as an independent company, after spurning a $118 billion takeover attempt by Pfizer. The trial looked at stage IV patients — those with the most advanced form of cancer.


A dissident group of Takeda Pharmaceutical (TKPYY) shareholders is making a final push to block its $62 billion acquisition of Shire (SHPG) by bringing in the most influential member of the Japanese pharmaceutical company’s founding family to support its campaign, The Financial Times reports. Kunio Takeda, a former Takeda chairman and the last member of the Takeda family to run the 237-year-old drug maker, opposes the takeover. The founding family members together own an estimated 10 percent of Takeda.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!